The FDA granted orphan drug designation to deupirfenidone, also known as LYT-100, for treating patients with idiopathic pulmonary fibrosis, according to a press release from PureTech Health.The ...
Deupirfenidone, a potential new treatment for idiopathic pulmonary fibrosis, is set to be tested in a phase 3 trial this year after a successful phase 2b trial and meeting with the FDA, according to a ...
Mendelian randomization revealed a potential protective role of IPF against large artery atherosclerosis stroke, but no significant links with other cardiovascular diseases. The study suggests ...
Shares of United Therapeutics UTHR surged 33% on Tuesday after it announced positive top-line results from the late-stage TETON-2 study evaluating the nebulized version of Tyvaso (treprostinil) in ...
Evaluating quality of life (QOL) in patients with idiopathic pulmonary fibrosis (IPF) goes beyond lung function numbers. It also shows how treatments affect daily well-being and guides funding, ...
VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian ...
IPF study will evaluate efficacy of two doses of LYT-100, one with comparable exposure to FDA-approved dose of pirfenidone and one with higher exposure, vs. placebo, as well as relative tolerability ...
FibroGen is focused on developing pamrevlumab, an innovative drug with potential for IPF treatment, which could capture a share of the multi-billion dollar IPF drug market. The PRAISE study showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results